Ipca Laboratories Limited

NSE:IPCALAB.NS

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

💻 Telehealth

Location

India

Market Cap

USD 4.00 B

Share Price

USD 15.81

Avg Daily Volume

262,019

Change (1 day)

0.19%

Change (1 year)

19.44%

Change (YTD)

-20.16%

Ipca Laboratories Limited Operating Income Margin for the year ending March 31, 2025: 14.86%

Ipca Laboratories Limited Operating Income Margin is 14.86% for the year ending March 31, 2025, a -61.73% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Ipca Laboratories Limited Operating Income Margin for the year ending March 31, 2024 was 38.83%, a 244.72% change year over year.
Ipca Laboratories Limited Operating Income Margin for the year ending March 31, 2023 was 11.26%, a -38.88% change year over year.
Ipca Laboratories Limited Operating Income Margin for the year ending March 31, 2022 was 18.43%, a -24.01% change year over year.
Ipca Laboratories Limited Operating Income Margin for the year ending March 31, 2021 was 24.25%, a 48.46% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Operating Income Margin	Gross Profit Margin	EBIT Margin	EBITDA Margin

NSE: IPCALAB.NS

Ipca Laboratories Limited

CEO	Mr. Pranay Premchand Godha
IPO Date	Jan. 1, 1996
Location	India
Headquarters	125, Kandivli Industrial Estate
Employees	17,335
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies 💻 Telehealth

Description

Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.